At a time where access to human antibody engineering technology was difficult, our co-founders found opportunity where scientific discovery met a new approach to innovation. Hear from Tim Hauwermeiren, CEO, and Hans de Haard, Chief Scientific Officer on how argenx grew from an idea to a global immunology company.
Discover Related Stories
Explore more about work to chart a new course in immunology
Follow us
Get the latest news and info via our social media channels.